Literature DB >> 3114637

Prevention and reversal of nitrate tolerance in patients with congestive heart failure.

M Packer, W H Lee, P D Kessler, S S Gottlieb, N Medina, M Yushak.   

Abstract

To evaluate possible mechanisms underlying the development of nitrate tolerance, we treated 35 patients who had severe chronic heart failure with a prolonged (48-hour) intravenous infusion of nitroglycerin (6.4 micrograms per kilogram of body weight per minute) given either continuously or intermittently (12-hour infusions separated by intervals of 12 hours). Intravenous nitroglycerin produced immediate hemodynamic benefits in all patients, but the magnitude of this improvement was greatly diminished after 48 hours of continuous therapy with the drug. This attenuation was accompanied by cross-tolerance to oral isosorbide dinitrate and by an increase in heart rate, plasma renin activity, and body weight. In contrast, intermittent therapy with intravenous nitroglycerin was not associated with a loss of hemodynamic efficacy or cross-tolerance to oral nitrates and was not accompanied by changes in neurohormonal activity or body weight. In eight patients in whom nitrate tolerance developed during continuous intravenous therapy, the administration of the sulfhydryl-containing compound N-acetylcysteine (200 mg per kilogram orally) restored the hemodynamic state toward that observed at the start of the infusion of nitroglycerin (partial reversal of tolerance). In contrast, N-acetylcysteine had little hemodynamic effect in patients who were not receiving nitroglycerin. These data support the hypothesis that neurohormonal activation and depletion of sulfhydryl groups may interact to cause the loss of hemodynamic efficacy that occurs during prolonged treatment with intravenous nitroglycerin in patients with heart failure. Evaluation of the suggested role of sulfhydryl depletion in the development of tolerance will, however, require direct studies of vascular tissue.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114637     DOI: 10.1056/NEJM198709243171304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  67 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Effects of N-acetylcysteine on nitroglycerin-induced relaxation and protein phosphorylation of porcine coronary arteries.

Authors:  Y Tate; K Kawasaki; S Ishibashi; U Ikeda; K Shimada
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 3.  An update on nitrate tolerance: can it be avoided?

Authors:  S R Maxwell; M J Kendall
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

Review 4.  Soluble guanylate cyclase modulators in heart failure.

Authors:  Veselin Mitrovic; Ana Jovanovic; Stefan Lehinant
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 5.  Mechanisms of nitrate tolerance: a review.

Authors:  R J Katz
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 6.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

Review 7.  Update on nitrate tolerance.

Authors:  J O Parker
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

Review 8.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers.

Authors:  J C Hogan; M J Lewis; A H Henderson
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

10.  S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators.

Authors:  P J Henry; O H Drummer; J D Horowitz
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.